bexarotene has been researched along with Cognitive Dysfunction in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Chen, G; Chi, T; Du, F; Gao, J; Guo, X; Ji, X; Jiang, W; Lang, H; Liu, D; Liu, P; Qiu, S; Tang, X; Xu, J; Yang, Y; Yuan, C; Zhou, Q; Zhou, X; Zou, L | 1 |
1 other study(ies) available for bexarotene and Cognitive Dysfunction
| Article | Year |
|---|---|
OAB-14, a bexarotene derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Apolipoproteins E; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; Bexarotene; Body Weight; CD36 Antigens; Cerebral Cortex; Cognitive Dysfunction; Hippocampus; Humans; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Neuronal Plasticity; Peptide Fragments; Presenilin-1 | 2019 |